stockrow
Friday 6 November 2026
Export IMNM’s income statement to Excel — free account
Immunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
18.65
0.74
+4.13%
Follow IMNM
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
8.67 | 14.53 | 21.26 | 14.56 | |
Current Ratio |
8.90 | 14.69 | 21.68 | 15.08 | |
Net Debt/EBITDA |
4.53 | 9.07 | 9.95 | 6.72 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.71 | 0.69 | 1.09 | 0.84 | |
Capex/Depreciation |
13.45 | (5.15) | (3.99) | (3.04) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.46) | (0.55) | (0.52) | (0.54) | |
Capex per Share |
(0.01) | (0.05) | (0.03) | (0.02) | |
Free Cash Flow per Share |
(0.47) | (0.59) | (0.54) | (0.56) | |
Cash per Share |
3.10 | 7.48 | 5.15 | 4.59 | |
Shareholders Equity per Share |
3.00 | 7.26 | 5.20 | 4.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.00 | 7.26 | 5.20 | 4.64 | |
Free Cash Flow |
(41.63) | (51.95) | (61.64) | (63.87) | |
Working Capital |
248.48 | 615.79 | 566.90 | 502.74 | |
Capital Expenditures |
(1.12) | (4.00) | (3.00) | (2.18) | |
Net Current Asset Value |
244.47 | 611.93 | 563.20 | 498.15 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.83 | 8.76 | 7.33 | 5.33 | |
Average Assets |
278.14 | 461.71 | 481.24 | 430.84 | |
Average Common Equity |
239.41 | 407.75 | 447.91 | 397.18 |
Columns are period end dates